Navigation Links
Halozyme Therapeutics to Present at Upcoming Financial Conferences
Date:9/1/2011

SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at two upcoming financial conferences, the William Blair Life Sciences Conference in New York and the Stifel Nicolaus Healthcare Conference in Boston.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The William Blair Life Sciences Conference presentation is scheduled for Wednesday, September 7 at 11:30 a.m. EDT (8:30 a.m. PDT).

The Stifel Nicolaus Healthcare Conference is scheduled for Thursday, September 8 at 8:35 a.m. EDT (5:35 a.m. PDT).

To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. A replay will be available for 90 days after the event.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin, Cinryze® and recombinant human alpha 1-antitrypsin. Halozym
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17
2. Halozymes Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
3. Halozyme and Intrexon Announce Collaboration to Develop First Subcutaneous Recombinant Alpha 1-Antitrypsin Replacement Therapy
4. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
5. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
6. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
7. Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
9. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
10. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
11. Halozyme Therapeutics Realigns Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... VIEW, Calif. , Aug. 31, 2015 /PRNewswire/ ... for flow cytometry is experiencing a rise in ... the demand in underdeveloped nations to quantitate CD4 ... Logo - http://photos.prnewswire.com/prnh/20150831/262206LOGO ... Analysis of the Global Flow Cytometry Market ( ...
(Date:8/31/2015)... HARRISBURG, Pa. , Aug. 31, 2015 ... been reversed statewide since Pennsylvania ... the life-saving drug kits, naloxone. Heroin and ... in Pennsylvania , killing more individuals ... 2013, approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... , Aug. 31, 2015  The departments of ... event today at Gaudenzia Concept 90 to raise awareness ... overdose crisis in Pennsylvania and ... and focus on recovery through the Building Bridges ... Pennsylvanians are dying every day to a disease that ...
Breaking Medicine Technology:Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2
... Phase 1 Colorectal and Prostate Cancer,Trials To Be ... FRANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, ... announced that data from a Phase 2 trial,of ... small cell lung cancer (SCLC) will be presented ...
... Urine Flow, With,Long Lasting Effect in Phase 2 ... Spectrum,Pharmaceuticals, Inc., today announced Phase 2 safety and ... the treatment,of benign prostatic hypertrophy (BPH), at the ... Convention Center in,Anaheim, California on Tuesday, May 22, ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 2Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 3Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 4Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 2Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 3Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 4Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 5
(Date:9/1/2015)... ... 01, 2015 , ... METTLER TOLEDO is pleased to announce ... Connectivity Kit, EasySampler data is automatically transferred to, and reported with, the referring ... platform. , EasySampler fully automates the sampling process including sampling capture, ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... more than 1,500 investor-families have received permanent green cards (I-829 petition approval) from ... The I-829 petition is the final step of the EB-5 visa process for ...
(Date:9/1/2015)... ... September 01, 2015 , ... USA Medical Card, a ... week to coincide with back-to-school and the start of “sick season” for many ... elementary school children are sick an average of 8 to 12 times each ...
(Date:9/1/2015)... ... September 01, 2015 , ... AdvantagePlusCaregivers.com® ... to access caregivers and what to look for and expect when searching for ... Founded in 2006 in Canoga Park, CA by CEO, Richard Weatherman and Co-Founder ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... for Alfresco, a next-generation customer communications archiving solution integrated with Alfresco‘s enterprise ... from Crawford and helps organizations save millions of dollars in printing costs ...
Breaking Medicine News(10 mins):Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2Health News:USA Medical Card Launches New FAQ Video During Back-to-School 2Health News:AdvantagePlusCaregivers.com® Launches New Website for Corporate and Franchisee Locations in 3 States 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 3
... a non-profit organization focused on supporting innovative early ... at its fall Fellowship Award Committee review. ... outstanding postdoctoral scientists conducting basic and translational cancer ... across the country. The Fellowship encourages the nation,s ...
... Mozes HealthDay Reporter , WEDNESDAY, Jan. 5 (HealthDay ... amounts of vigorous physical exercise appear to lower their risk ... hours a week or more of vigorous biking, tennis, jogging ... the research team found. But they added that even moderate ...
... 5 (HealthDay News) -- The number of American adults treated for ... 9 million to 19 million, says a federal government report released ... diabetes increased from 4.3 million to 8 million among people age ... 45 to 64; and 1.2 million to 2.4 million among people ...
... Gehrig,s disease, or amyotrophic lateral sclerosis (ALS), and frontotemporal ... brain and spinal-cord cells that include an RNA-binding protein ... of the lesions formed by these clumps. ... Clinical Investigation , a team led by Virginia M.-Y. ...
... HealthDay Reporter , WEDNESDAY, Jan. 5 (HealthDay News) ... be treatable with a vaccine that has been engineered ... with a cocaine-like substance that mimics cocaine,s molecular composition. ... effective and long-lasting antibody immune response, attacking cocaine molecules ...
... at Mount Sinai School of Medicine has developed the ... This instrument has recently been used by soldiers returning ... in the Sixth Annual Road to Recovery Conference and ... TBI. "Traumatic brain injury is underdiagnosed, and ...
Cached Medicine News:Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 3Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 12 top young scientists 4Health News:Exercise May Improve Odds Against Prostate Cancer Death 2Health News:Exercise May Improve Odds Against Prostate Cancer Death 3Health News:Exercise May Improve Odds Against Prostate Cancer Death 4Health News:Diabetes Soaring Among American Adults: Report 2Health News:Malfunctioning gene associated with Lou Gehrig's disease leads to nerve-cell death in mice 2Health News:Vaccine Protects Mice From Cocaine's Effects, Study Finds 2Health News:Vaccine Protects Mice From Cocaine's Effects, Study Finds 3Health News:Mount Sinai develops first screening tool for war veterans to assess traumatic brain injury 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: